New York State Common Retirement Fund reduced its stake in Surmodics, Inc. (NASDAQ:SRDX) by 0.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,300 shares of the company’s stock after selling 1 shares during the quarter. New York State Common Retirement Fund owned 0.12% of Surmodics worth $431,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Trigran Investments Inc. lifted its position in Surmodics by 17.6% in the 2nd quarter. Trigran Investments Inc. now owns 1,258,613 shares of the company’s stock valued at $35,430,000 after acquiring an additional 188,114 shares in the last quarter. Vanguard Group Inc. lifted its position in Surmodics by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 694,114 shares of the company’s stock valued at $16,693,000 after acquiring an additional 30,518 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Surmodics by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 600,421 shares of the company’s stock valued at $14,440,000 after acquiring an additional 12,497 shares in the last quarter. Royce & Associates LP lifted its position in Surmodics by 1.3% in the 2nd quarter. Royce & Associates LP now owns 372,792 shares of the company’s stock valued at $10,494,000 after acquiring an additional 4,700 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Surmodics by 4.9% in the 1st quarter. Geode Capital Management LLC now owns 164,452 shares of the company’s stock valued at $3,954,000 after buying an additional 7,607 shares during the last quarter. 84.83% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/15/new-york-state-common-retirement-fund-cuts-position-in-surmodics-inc-srdx.html.

Shares of Surmodics, Inc. (NASDAQ:SRDX) opened at $29.40 on Wednesday. Surmodics, Inc. has a 52 week low of $21.90 and a 52 week high of $32.80. The stock has a market cap of $386.73, a price-to-earnings ratio of 57.16 and a beta of 0.78.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.19. Surmodics had a net margin of 5.37% and a return on equity of 6.18%. The firm had revenue of $20.06 million for the quarter, compared to analyst estimates of $16.98 million. equities research analysts expect that Surmodics, Inc. will post -0.28 EPS for the current year.

Several equities research analysts have issued reports on the stock. ValuEngine lowered shares of Surmodics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. BidaskClub upgraded shares of Surmodics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $40.00.

In other news, VP Joseph J. Stich sold 1,000 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $27.28, for a total transaction of $27,280.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 6.40% of the stock is currently owned by insiders.

Surmodics Profile

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Surmodics, Inc. (NASDAQ:SRDX).

Institutional Ownership by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Stock Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related stocks with our FREE daily email newsletter.